LitCovid-sample-Enju  

PMC:7228307 / 57351-58032 JSONTXT 11 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T0 0-3 DT denotes The
T1 4-14 NN denotes expression
T2 15-17 IN denotes of
T3 18-25 NN denotes FcγRIIb
T4 26-28 IN denotes on
T5 29-33 NNP denotes LSEC
T6 34-37 CC denotes and
T7 38-41 PRP-DOLLAR- denotes its
T8 42-48 NN denotes action
T9 49-51 IN denotes in
T10 52-55 DT denotes the
T11 56-66 NN denotes “sweeping”
T12 67-69 CC denotes or
T13 70-77 NN denotes removal
T14 78-80 IN denotes of
T15 81-86 JJ denotes small
T16 87-93 JJ denotes immune
T17 94-103 NNS denotes complexes
T18 104-107 VBZ denotes has
T19 108-114 VBN denotes opened
T20 115-117 RP denotes up
T21 118-121 JJ denotes new
T22 122-135 NNS denotes possibilities
T23 136-139 IN denotes for
T24 140-143 DT denotes the
T25 144-155 NN denotes application
T26 156-158 IN denotes of
T27 159-176 VBG denotes FcγRIIb‐enhancing
T28 177-193 NN denotes modifications.17
T29 194-204 NNS denotes Antibodies
T30 205-207 CC denotes or
T31 208-210 NN denotes Fc
T32 211-217 NN denotes fusion
T33 218-226 NNS denotes proteins
T34 226-227 -COMMA- denotes ,
T35 228-233 WP-DOLLAR- denotes whose
T36 234-241 JJ denotes primary
T37 242-245 NN denotes MOA
T38 246-248 VBZ denotes is
T39 249-252 DT denotes the
T40 253-267 NN denotes neutralization
T41 268-270 IN denotes of
T42 271-278 JJ denotes soluble
T43 279-288 NNS denotes molecules
T44 289-293 JJ denotes such
T45 294-296 IN denotes as
T46 297-300 NN denotes IgE
T47 301-303 CC denotes or
T48 304-313 NNS denotes cytokines
T49 313-314 -COMMA- denotes ,
T50 315-318 VBP denotes are
T51 319-331 RB denotes particularly
T52 332-342 JJ denotes attractive
T53 343-353 NNS denotes candidates
T54 354-357 IN denotes for
T55 358-362 DT denotes this
T56 363-371 NN denotes approach
T57 373-389 NN denotes Proof‐of‐concept
T58 390-393 IN denotes for
T59 394-398 DT denotes this
T60 399-407 NN denotes strategy
T61 408-411 VBZ denotes has
T62 412-416 VBN denotes been
T63 417-429 VBN denotes demonstrated
T64 430-432 IN denotes in
T65 433-445 JJ denotes experimental
T66 446-455 NN denotes models.48
T67 456-462 RB denotes Indeed
T68 462-463 -COMMA- denotes ,
T69 464-468 DT denotes this
T70 469-472 MD denotes may
T71 473-475 VB denotes be
T72 476-477 DT denotes a
T73 478-489 JJ denotes significant
T74 490-499 NN denotes component
T75 500-502 IN denotes of
T76 503-506 DT denotes the
T77 507-512 JJ denotes rapid
T78 513-526 NN denotes disappearance
T79 527-529 IN denotes of
T80 530-533 NN denotes IgE
T81 534-538 IN denotes from
T82 539-542 DT denotes the
T83 543-554 NN denotes circulation
T84 555-557 IN denotes of
T85 558-566 NNS denotes patients
T86 567-574 VBN denotes treated
T87 575-579 IN denotes with
T88 580-583 DT denotes the
T89 584-592 NN denotes anti‐IgE
T90 593-601 NN denotes XmAb7195
T91 602-612 VBG denotes containing
T92 613-616 DT denotes the
T93 617-624 NN denotes FcγRIIb
T94 625-634 VBG denotes enhancing
T95 635-641 NNP denotes “SELF”
T96 642-655 NNS denotes modifications
T97 655-656 -COMMA- denotes ,
T98 657-659 IN denotes as
T99 660-669 VBN denotes described
T100 670-680 RB denotes previously
R0 T1 T0 arg1Of expression,The
R1 T1 T2 arg1Of expression,of
R10 T12 T10 arg1Of or,the
R100 T94 T97 arg1Of enhancing,","
R101 T94 T98 arg1Of enhancing,as
R102 T99 T98 arg2Of described,as
R103 T99 T100 arg1Of described,previously
R11 T11 T12 arg1Of “sweeping”,or
R12 T13 T12 arg2Of removal,or
R13 T12 T14 arg1Of or,of
R14 T17 T14 arg2Of complexes,of
R15 T17 T15 arg1Of complexes,small
R16 T17 T16 arg1Of complexes,immune
R17 T6 T18 arg1Of and,has
R18 T19 T18 arg2Of opened,has
R19 T6 T19 arg1Of and,opened
R2 T3 T2 arg2Of FcγRIIb,of
R20 T22 T19 arg2Of possibilities,opened
R21 T19 T20 arg1Of opened,up
R22 T22 T21 arg1Of possibilities,new
R23 T22 T23 arg1Of possibilities,for
R24 T25 T23 arg2Of application,for
R25 T25 T24 arg1Of application,the
R26 T25 T26 arg1Of application,of
R27 T30 T26 arg2Of or,of
R28 T29 T27 arg1Of Antibodies,FcγRIIb‐enhancing
R29 T29 T28 arg1Of Antibodies,modifications.17
R3 T1 T4 arg1Of expression,on
R30 T29 T30 arg1Of Antibodies,or
R31 T33 T30 arg2Of proteins,or
R32 T33 T31 arg1Of proteins,Fc
R33 T33 T32 arg1Of proteins,fusion
R34 T22 T34 arg1Of possibilities,","
R35 T37 T35 arg1Of MOA,whose
R36 T22 T35 arg2Of possibilities,whose
R37 T37 T36 arg1Of MOA,primary
R38 T37 T38 arg1Of MOA,is
R39 T40 T38 arg2Of neutralization,is
R4 T5 T4 arg2Of LSEC,on
R40 T40 T39 arg1Of neutralization,the
R41 T40 T41 arg1Of neutralization,of
R42 T43 T41 arg2Of molecules,of
R43 T43 T42 arg1Of molecules,soluble
R44 T45 T44 arg1Of as,such
R45 T43 T45 arg1Of molecules,as
R46 T47 T45 arg2Of or,as
R47 T46 T47 arg1Of IgE,or
R48 T48 T47 arg2Of cytokines,or
R49 T38 T49 arg1Of is,","
R5 T1 T6 arg1Of expression,and
R50 T50 T49 arg2Of are,","
R51 T37 T50 arg1Of MOA,are
R52 T53 T50 arg2Of candidates,are
R53 T52 T51 arg1Of attractive,particularly
R54 T53 T52 arg1Of candidates,attractive
R55 T53 T54 arg1Of candidates,for
R56 T56 T54 arg2Of approach,for
R57 T56 T55 arg1Of approach,this
R58 T57 T58 arg1Of Proof‐of‐concept,for
R59 T60 T58 arg2Of strategy,for
R6 T8 T6 arg2Of action,and
R60 T60 T59 arg1Of strategy,this
R61 T57 T61 arg1Of Proof‐of‐concept,has
R62 T63 T61 arg2Of demonstrated,has
R63 T57 T62 arg1Of Proof‐of‐concept,been
R64 T63 T62 arg2Of demonstrated,been
R65 T57 T63 arg2Of Proof‐of‐concept,demonstrated
R66 T63 T64 arg1Of demonstrated,in
R67 T66 T64 arg2Of models.48,in
R68 T66 T65 arg1Of models.48,experimental
R69 T66 T67 arg1Of models.48,Indeed
R7 T8 T7 arg1Of action,its
R70 T63 T68 arg1Of demonstrated,","
R71 T71 T68 arg2Of be,","
R72 T69 T70 arg1Of this,may
R73 T71 T70 arg2Of be,may
R74 T69 T71 arg1Of this,be
R75 T74 T71 arg2Of component,be
R76 T74 T72 arg1Of component,a
R77 T74 T73 arg1Of component,significant
R78 T74 T75 arg1Of component,of
R79 T78 T75 arg2Of disappearance,of
R8 T8 T9 arg1Of action,in
R80 T78 T76 arg1Of disappearance,the
R81 T78 T77 arg1Of disappearance,rapid
R82 T78 T79 arg1Of disappearance,of
R83 T80 T79 arg2Of IgE,of
R84 T80 T81 arg1Of IgE,from
R85 T83 T81 arg2Of circulation,from
R86 T83 T82 arg1Of circulation,the
R87 T83 T84 arg1Of circulation,of
R88 T85 T84 arg2Of patients,of
R89 T85 T86 arg2Of patients,treated
R9 T12 T9 arg2Of or,in
R90 T86 T87 arg1Of treated,with
R91 T90 T87 arg2Of XmAb7195,with
R92 T90 T88 arg1Of XmAb7195,the
R93 T90 T89 arg1Of XmAb7195,anti‐IgE
R94 T90 T91 arg1Of XmAb7195,containing
R95 T93 T91 arg2Of FcγRIIb,containing
R96 T93 T92 arg1Of FcγRIIb,the
R97 T93 T94 arg1Of FcγRIIb,enhancing
R98 T96 T94 arg2Of modifications,enhancing
R99 T96 T95 arg1Of modifications,“SELF”